Sirtuin1: A Promising Serum Protein Marker for Early Detection of Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kumar, Rahul ^a   Chaterjee, Prasun ^a   Sharma, Prakash K ^a   Singh, Abhay K ^a   Gupta, Abhishek ^a   Gill, Kamaldeep ^a   Tripathi, Manjari ^a   Dey, Aparajit B ^a   Dey, Sharmistha ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; SIRTUIN 1;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; SIRTUIN 1;

EID: 84876185003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061560     Document Type: Article

References (26)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
2. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
3. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, et al. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771-776.
4. Qin W, Yang T, Ho L, Zhao Z, Wang J, et al. (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281: 21745-52174.
5. Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, et al. (2005) Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging 26: 995-1000.
6. Guarente L, (2008) Mitochondria-a nexus for aging, calorie restriction, and sirtuins? Cell 132: 171-176.
7. Bonda DJ, Lee HG, Camins A, Pallàs M, Casadesus G, et al. (2011) The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurology 10: 275-279].
8. Donmez G, Diana W, Cohen DE, Guarente L, (2010) SIRT1 Suppresses β-Amyloid Production by Activating the α-Secretase Gene ADAM10. Cell 142: 320-332.
9. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N Jr, et al. (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68: 48-58.
10. Kumar R, Singh AK, Pandey R, Dey S, (2012) Cloning expression and purification of human truncated SIRT1. Int J Mol Bio 3: 49-54.
11. The Dementia India Report (2010)- Prevalence, impact, costs and services for dementia. New Delhi: Alzheimer's and Related Disorders Society of India, 2010.
12. Petersen RC, (1995) Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologist 1: 326-344.
13. Flicker C, Ferris SH, Reisberg B, (1991) Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 41: 1006-1009.
14. Jorm AF, (1991) Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci 240: 218-222.
15. Kemnitz JW, (2011) Calorie restriction and aging in nonhuman primates. ILAR J. 52: 66-77.
16. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
17. Luis CA, Abdullah L, Paris D, Quadros A, Mullan M, et al. (2009) Serum beta-amyloid correlates with neuropsychological impairment. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 16: 203-218.
18. Schneider P, Hampel H, Buerger K, (2009) Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther. 15: 358-374.
19. Kim D, Nguyen MD, Dobbin MM, Sananbenesi F, Rodgers JT, et al. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. Embo J 26: 3169-3179.
20. Albani D, Polito L, Forloni G, (2011) Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers Dis 19: 11-26.
21. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, March RH, et al. (2010) Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc Natl Acad Sci U S A 107: 17763-7.
22. Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, et al. (2008) The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 134: 329-340.
23. Prinzen C, Muller U, Endres K, Fahrenholz F, Postina R, (2005) Genomic structure and functional characterization of the human ADAM10 promoter. Faseb J 19: 1522-1524.
24. Taylor WH, (1969) Serum enzymes in the diagnosis of disease. Br J Anaesth 41: 227-34.
25. Anderson NL, Anderson NG, (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1: 845-867.
26. Thadikkaran L, Siegenthaler MA, Crettaz D, Queloz PA, Schneider P, et al. (2005) Recent advances in blood-related proteomics. Proteomics 5: 3019-3034.